ホーム>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>S-trityl-L-Cysteine

S-trityl-L-Cysteine (Synonyms: NSC 83265)

カタログ番号GC40932

S-トリチル-L-システイン (NSC 83265) は、選択的かつアロステリックなキネシン Eg5 阻害剤であり、基底 ATPase 活性の阻害に対する IC50 は 1 μM、微小管活性化 ATPase 活性に対する IC50 は 140 nM です。 S-トリチル-L-システインには抗腫瘍活性があります。

Products are for research use only. Not for human use. We do not sell to patients.

S-trityl-L-Cysteine 化学構造

Cas No.: 2799/7/7

サイズ 価格 在庫数 個数
1g
$25.00
在庫あり
5g
$80.00
在庫あり
10g
$148.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

S-trityl-L-Cysteine is a non-natural amino acid and an inhibitor of Eg5, also known as KSP and Kif11, a mitotic kinesin necessary for mitotic spindle formation. S-trityl-L-Cysteine inhibits the ATPase activity of Eg5 in basal and microtubule-stimulated states (IC50s = 1,000 and 140 nM, respectively). It is selective for Eg5 over nine other human kinesins in an enzyme-coupled assay. It reversibly inhibits Eg5-driven microtubule sliding velocity with an IC50 value of 500 nM using X. laevis recombinant Eg5. It induces cell cycle arrest in HeLa cells (IC50 = 700 nM), reversibly halting the cell cycle in the mitotic phase by inhibiting the separation of duplicated chromosomes and preventing bipolar spindle formation. S-trityl-L-Cysteine inhibits the growth of cancer cells in vitro when tested against the National Cancer Institute (NCI) 60 human cancer cell line panel (average GI50 = 1.3 µM) and in mouse xenograft models.

レビュー

Review for S-trityl-L-Cysteine

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for S-trityl-L-Cysteine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.